首页/数据集/Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

Mendeley Data2026-04-18 收录

化疗诱导毒性红斑亚型

不良药物反应

数据链接：

https://data.mendeley.com/datasets/65cjrm6xkm 数据链接链接失效反馈

官方服务：

资源简介：

Supplemental Appendix

补充附录

应用场景：

创建时间：

2021-01-28

不良药物反应

临床工具验证

Annals of Pharmacotherapy published adverse drug reaction case reports assessed using the Liverpool ADR Causality Assessment Tool. (DOC)

NIAID Data Ecosystem100

Supplementary Material for: Adverse Cutaneous Reactions to Monoclonal Antibodies: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Erythema Multiforme, and Fixed Drug Eruption – A Systematic Review

不良药物反应

单克隆抗体

Background The therapeutic use of monoclonal antibodies (mAbs) has significantly increased since the first mAb was introduced. Despite their therapeutic benefits, mAbs have been accompanied by a rise

DataCite Commons2025-04-19 更新40

428 PTs that met the four assessment criteria.

药物安全监测

不良药物反应

BackgroundThis study aims to assess the adverse events (AEs) and safety profile of omeprazole, a widely used proton pump inhibitor (PPI) for acid-related diseases. Despite being a first-line treatment

Figshare2025-08-20 更新30

Summary of adverse events reported by owners during the course of the study.

兽药安全性监测

不良药物反应

Listed are the number of cats with each sign while on placebo and while on meloxicam treatment. In addition, for any adverse event where cats were removed from the study prior to Day78 predominantly d

NIAID Data Ecosystem80

Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer.

转移性结直肠癌化疗

不良药物反应

Interventions: Alternate-day S-1 (80mg/m2; day 2,4,6...14) combined with irinotecan (150mg/m2; day 1) and bevacizumab (5.0 mg/kg; day 1) Primary outcome(s): Incidence of grade 3 or 4 diarrhea Study De

NIAID Data Ecosystem40

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

资源简介：

相关数据集